$BTDG NEWS! B2Digital Congratulates B2FS Champion Cameron

A Triathlete with Grit and Ambition Mako Hiraizumi didn't just earn a silver medal at the 32nd Japan Triathlon National Championships; she set an example of perseverance and ambition. Rising a notch from her bronze finish last year, Hiraizumi's runner-up achievement at Tokyo's Odaiba Seaside Park is no small feat. Yet, she's not resting on her laurels. This athlete from...

Seagems Joint Venture Snags Petrobras Contract Let’s dive headfirst into this business update, because this one's got teeth, folks. Petrobras, the big dog in Brazil’s oil arena, has given the green light to Seagems’ bid, a joint venture half-owned by Paratus Energy Services Ltd. The target? A hefty pipe-laying support vessel (PLSV) contract starting in 2028. But...

Paving New Paths in Biotech Collaboration When a university and a biotech company shake hands to bolster their capabilities in the ever-evolving field of clinical trials and cell and gene therapies, investors and industry buffs alike should perk up. The College of Medicine at Princess Nourah bint Abdulrahman University (PNU) has just inked a Memorandum of Understanding...

Tuya's Third Quarter: What Are We Watching? Alright, folks, Tuya's about to drop their third quarter financial results like it's a hot potato. Circle November 23, 2026, on your calendars. That's when we'll get the goods on whether this AI cloud heavyweight is coasting or crushing it. Conference Call: The Gathering of Numbers The number-crunching brigade kickstarts at 7:30...

The Drill Down on Nevada Organic Phosphate's Strategic Moves There's a lot to unpack here as Nevada Organic Phosphate Inc. (CSE: NOP) rolls out its big game plan. They're looking to consolidate shares, flex their financial muscles, and maybe spray some high-octane fuel on their market positioning. Could be a smart move if they pull it off, but that's a big 'if' hanging in...

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

NextVision's financials this quarter are the envy of tech growth companies everywhere. Their Q3 2026 report reads like a thrilling playbook for success. No half-measures here—NextVision has doubled its revenue, slashed costs, and cooked up an operating margin fit for a kingpin. Pushing Revenue to New Heights NextVision didn’t just surpass last year's revenue; it...

They're gunning for glory in the sands of Baja, folks—Segway Powersports is about to rev up the excitement with its Baja 1000 debut. Never heard before in this legendary race's chronicles, Segway aims to shake up the game with their two brawny Super Villain UTVs. These aren't your run-of-the-pavement ride-ons; they're built for the rough stuff—and if there's a stage...

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Shifting Dynamics of America's Net Debtor Status By Jamie McGeever Foreign investment in the U.S. has consistently outnumbered American investments abroad for several decades. This persistent imbalance has raised concerns among analysts about potential repercussions for the dollar's confidence. Despite these warnings, the anticipated crisis regarding this dynamic has not...

Diving Deeper into Doximity's Short Interest Analysis Doximity (DOCS) has attracted attention in recent financial discussions due to its short interest metrics. Recently, it was reported that the short percent of float for Doximity has decreased by 4.22%. This decline translates to approximately 5.64 million shares sold short, constituting about 4.54% of the company’s...

Join Apogee Therapeutics' First Virtual R&D Day Apogee Therapeutics, Inc., a promising clinical-stage biotechnology firm, is poised to present its inaugural virtual Research and Development Day. Scheduled for 10:00 a.m. ET on a soon-to-come date, this event invites those interested in the transformative work happening in the field of biotechnology. Unveiling Innovations...

Oklahoma City School Choice Showcase Set to Inspire Families Students from around Oklahoma City are gearing up for a fantastic event at Dove Science Academy, with a heartfelt message highlighting their love for their schools. The exciting gathering will showcase K–12 school choice options available in the state, aligning perfectly with the celebratory spirit of National...

Comprehensive Insights from the 2024 Global Identity & Fraud Report Experian has unveiled its 2024 Global Identity & Fraud Report, delivering an in-depth analysis of consumer and business responses to prevailing fraud patterns as well as effective mitigation strategies within the financial services sector. This extensive report is backed by data accumulated from over...